Lyell Immunopharma
formerly LyellIPONext-Generation CAR-T Cell Therapies for Cancer | Lyell
Public · South San Francisco, United States · Founded 2018 · $884.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 201–500
- Founded
- 2018
- Business Model
- B2B
- Website
- lyell.com
- Total Funding
- $884.0M
- Last Round
- $50.0M Venture RoundJul 2025
- Rounds
- 6
- Type
- Public
About
Lyell Immunopharma is a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. Founded in 2018 and headquartered in South San Francisco, Lyell combines proprietary genetic and epigenetic T-cell reprogramming technologies with an in-house manufacturing facility (LyFE Manufacturing Center) to create potent, durable cell therapies designed to deliver lasting remissions with a single treatment.
Summary
Lyell Immunopharma is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $884.0M in total across 6 rounds, most recently a $50.0M Venture Round round in Jul 2025. Investors include GV, ARCH Venture Partners and Foresite Capital.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jul 2025
Sign up to see all 7 rounds
Seed through Venture Round — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/lyell-immunopharma"><img src="https://indexed.vc/api/badge/company/lyell-immunopharma" alt="Lyell Immunopharma on Indexed.vc" width="260" height="76" /></a>